^
BIOMARKER:

FGFR mutation

i
Other names: FGFR, Fibroblast Growth Factor Receptor
Related biomarkers:
Phase 2
Janssen Research & Development, LLC
Recruiting
Last update posted :
12/31/2021
Initiation :
02/28/2020
Primary completion :
10/26/2022
Completion :
08/11/2027
FGFR
|
FGFR mutation • FGFR fusion
|
gemcitabine • Balversa (erdafitinib) • mitomycin
Phase 2
Incyte Corporation
Recruiting
Last update posted :
12/22/2021
Initiation :
01/26/2021
Primary completion :
08/26/2023
Completion :
11/08/2023
PD-L1 • POLE
|
PD-L1 expression • MSI-H/dMMR • FGFR1 mutation • FGFR mutation
|
Pemazyre (pemigatinib) • epacadostat (INCB024360) • retifanlimab (INCMGA0012)
Phase 2
Five Prime Therapeutics, Inc.
Withdrawn
Last update posted :
12/13/2021
Initiation :
01/01/2011
Primary completion :
06/01/2012
Completion :
12/01/2012
FGFR2 • FGFR
|
FGFR2 mutation • FGFR mutation • FGFR2 S252W
|
FP-1039
Phase 1/2
Incyte Biosciences International Sàrl
Active, not recruiting
Last update posted :
12/10/2021
Initiation :
01/29/2020
Primary completion :
07/31/2023
Completion :
10/01/2024
RET • KIT • FGFR
|
EGFR mutation • KIT mutation • RET mutation • FGFR mutation
|
Iclusig (ponatinib)
Phase 2
Janssen Research & Development, LLC
Recruiting
Last update posted :
12/03/2021
Initiation :
11/20/2019
Primary completion :
06/14/2022
Completion :
11/30/2027
FGFR
|
FGFR mutation • FGFR fusion
|
Balversa (erdafitinib)
Phase 2
TransThera Sciences (Nanjing), Inc.
Not yet recruiting
Last update posted :
10/26/2021
Initiation :
10/01/2021
Primary completion :
12/01/2022
Completion :
09/01/2023
FGFR2
|
FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR mutation • FGFR1 fusion • FGFR wild-type
|
TT-00420
Phase 2
National Cancer Center, Japan
Recruiting
Last update posted :
10/22/2021
Initiation :
06/15/2021
Primary completion :
12/31/2024
Completion :
12/31/2024
EGFR • BRAF • KRAS • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK
|
EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • FGFR2 mutation • FGFR2 fusion • FGFR2 N549K • FGFR mutation • FGFR1 fusion • FGFR3 fusion • FGFR2 P253R • FGFR2 K310R • FGFR3 Y375C • FGFR2 C382R • FGFR2 S252W • FGFR3 G380R • FGFR3 K650E • FGFR2 W290C • FGFR2 Y375C
|
E7090
Phase 2
European Association of Urology Research Founda...
Recruiting
Last update posted :
08/16/2021
Initiation :
07/13/2020
Primary completion :
04/30/2024
Completion :
10/30/2024
FGFR
|
FGFR mutation
|
cisplatin • Pemazyre (pemigatinib)
Phase 2
Sun Yat-sen University
Recruiting
Last update posted :
06/23/2021
Initiation :
06/16/2021
Primary completion :
06/01/2023
Completion :
06/01/2025
HER-2 • ER
|
ER positive • HER-2 negative • FGFR1 amplification • FGFR mutation
|
Focus V (anlotinib) • fulvestrant
Phase 2a
Janssen Research & Development, LLC
Active, not recruiting
Last update posted :
05/27/2021
Initiation :
07/08/2016
Primary completion :
12/31/2021
Completion :
12/31/2021
FGFR
|
FGFR mutation
|
Balversa (erdafitinib)
Phase 
Ho Kyung Seo
Not yet recruiting
Last update posted :
04/09/2020
Initiation :
05/01/2020
Primary completion :
03/31/2022
Completion :
03/31/2025
PD-L1 • FGFR
|
PD-L1 expression • FGFR mutation
Phase 2
Sameek Roychowdhury
Recruiting
Last update posted :
02/17/2020
Initiation :
02/24/2015
Primary completion :
12/31/2021
Completion :
12/31/2021
FLT3 • ABL1 • RET • PDGFRA • FGFR
|
FGFR mutation • FGFR fusion
|
Iclusig (ponatinib)
Phase 4
Samsung Medical Center
Recruiting
Last update posted :
12/30/2019
Initiation :
11/20/2017
Primary completion :
12/01/2020
Completion :
12/01/2020
RET
|
RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive
|
Sutent (sunitinib)
Phase N/A
Shanghai Changzheng Hospital
Recruiting
Last update posted :
04/29/2019
Initiation :
07/01/2019
Primary completion :
07/01/2020
Completion :
07/01/2023
FGFR
|
FGFR mutation
|
Focus V (anlotinib)